What does ZELLIK PHARMA do?

ZELLIK PHARMA is a pharmacy in Asse. Private Limited, started on 16 June 2006, 1 establishment.

What is the address of ZELLIK PHARMA?

The registered office of ZELLIK PHARMA is located at Brusselsesteenweg 812, 1731 Asse.

Is ZELLIK PHARMA still active?

Yes. According to the CBE (30 October 2026) ZELLIK PHARMA is active, legal situation “Normale toestand”, started on 16 June 2006.

Is ZELLIK PHARMA registered on Peppol?

Yes, ZELLIK PHARMA is registered on the Peppol network with ID 0208:0881910538.

What is the enterprise number of ZELLIK PHARMA?

The enterprise number of ZELLIK PHARMA is BE0881910538.

When was ZELLIK PHARMA founded?

ZELLIK PHARMA was founded on 16 June 2006.

Who are the directors of ZELLIK PHARMA?

According to the 2024 annual accounts, the directors of ZELLIK PHARMA are: Pharma Force NV.

Is ZELLIK PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 June 2006; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did ZELLIK PHARMA make in 2024?

ZELLIK PHARMA recorded a loss after taxes of € 93,373 in financial year 2024.

What is the revenue of ZELLIK PHARMA?

As a small company, ZELLIK PHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 393,644.

How much does an employee at ZELLIK PHARMA earn?

The average wage cost per full-time employee at ZELLIK PHARMA was € 51,000 in 2024: staff costs of € 454,224 for 8.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ZELLIK PHARMA have?

According to the 2024 annual accounts, ZELLIK PHARMA has 8.9 full-time equivalents (FTE).

ZELLIK PHARMA (Private Limited) - Asse - BE0881910538

Dossier ZELLIK PHARMA, printed on 30 October 2026 from databakkes.be/en/0881910538/zellik-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

ZELLIK PHARMA from Asse, company number BE0881910538, closed financial year 2024 with a result of € -93,373 after tax. For that financial year ZELLIK PHARMA recorded a gross margin of € 393,644 and equity of € 442,566. Compared with financial year 2023, the result moved from € 68,565 to € -93,373. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2025.

What it is worth Healthy

€ 442,566

▼ 17% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -93,373

▼ still € 68,565 profit in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 12,087

▲ 130% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 428,366.

People and assets in 2024

Full-time equivalents

8.9

▼ 0.5 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 454,224

▼ 8% vs 2023

€ 51,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 31,550

▼ 36% vs 2023

Of which on lease € 7,938.

Debts at end 2024

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 39,262

▼ 39% vs 2023

€ 17,385 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 172,407

▼ 58% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 76,495

▼ 14% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	€ 3,381,670 Revenue 2021: € 3,381,670 First fiscal year in the series	€ 3,434,270 Revenue 2022: € 3,434,270 ▲ 2% vs 2021 (€ 3,381,670) Favourable step	-	-
Gross margin	€ 513,921 Gross margin 2021: € 513,921 First fiscal year in the series	€ 599,255 Gross margin 2022: € 599,255 ▲ 17% vs 2021 (€ 513,921) Favourable step	€ 622,656 Gross margin 2023: € 622,656 ▲ 4% vs 2022 (€ 599,255) Favourable step	€ 393,644 Gross margin 2024: € 393,644 ▼ 37% vs 2023 (€ 622,656) Unfavourable step	▼ 37%
Profit after taxes	€ 115,718 Profit after taxes 2021: € 115,718 First fiscal year in the series	€ 110,430 Profit after taxes 2022: € 110,430 ▼ 5% vs 2021 (€ 115,718) Unfavourable step	€ 68,565 Profit after taxes 2023: € 68,565 ▼ 38% vs 2022 (€ 110,430) Unfavourable step	€ -93,373 Profit after taxes 2024: € -93,373 ▼ € 161,938 vs 2023 (€ 68,565) Unfavourable step	▼ € 161,938
Equity	€ 356,945 Equity 2021: € 356,945 First fiscal year in the series	€ 467,374 Equity 2022: € 467,374 ▲ 31% vs 2021 (€ 356,945) Favourable step	€ 535,939 Equity 2023: € 535,939 ▲ 15% vs 2022 (€ 467,374) Favourable step	€ 442,566 Equity 2024: € 442,566 ▼ 17% vs 2023 (€ 535,939) Unfavourable step	▼ 17%
Total debts	€ 962,709 Total debts 2021: € 962,709 First fiscal year in the series	€ 717,202 Total debts 2022: € 717,202 ▼ 26% vs 2021 (€ 962,709) Favourable step	€ 580,119 Total debts 2023: € 580,119 ▼ 19% vs 2022 (€ 717,202) Favourable step	€ 728,019 Total debts 2024: € 728,019 ▲ 25% vs 2023 (€ 580,119) Unfavourable step	▲ 25%
Cash	€ 25,537 Cash 2021: € 25,537 First fiscal year in the series	€ 2,946 Cash 2022: € 2,946 ▼ 88% vs 2021 (€ 25,537) Unfavourable step	€ 5,258 Cash 2023: € 5,258 ▲ 78% vs 2022 (€ 2,946) Favourable step	€ 12,087 Cash 2024: € 12,087 ▲ 130% vs 2023 (€ 5,258) Favourable step	▲ 130%
Retained profit	€ 342,745 Retained profit 2021: € 342,745 First fiscal year in the series	€ 453,174 Retained profit 2022: € 453,174 ▲ 32% vs 2021 (€ 342,745) Favourable step	€ 521,739 Retained profit 2023: € 521,739 ▲ 15% vs 2022 (€ 453,174) Favourable step	€ 428,366 Retained profit 2024: € 428,366 ▼ 18% vs 2023 (€ 521,739) Unfavourable step	▼ 18%
Bank debt	€ 50,384 Bank debt 2021: € 50,384 First fiscal year in the series	€ 63,917 Bank debt 2022: € 63,917 ▲ 27% vs 2021 (€ 50,384) Unfavourable step	€ 64,562 Bank debt 2023: € 64,562 ▲ 1% vs 2022 (€ 63,917) Unfavourable step	€ 39,262 Bank debt 2024: € 39,262 ▼ 39% vs 2023 (€ 64,562) Favourable step	▼ 39%
Balance sheet total	€ 1,319,653 Balance sheet total 2021: € 1,319,653 First fiscal year in the series	€ 1,184,576 Balance sheet total 2022: € 1,184,576 ▼ 10% vs 2021 (€ 1,319,653) Unchanged	€ 1,116,059 Balance sheet total 2023: € 1,116,059 ▼ 6% vs 2022 (€ 1,184,576) Unchanged	€ 1,170,585 Balance sheet total 2024: € 1,170,585 ▲ 5% vs 2023 (€ 1,116,059) Unchanged	▲ 5%
Employees (FTE)	6.7 Employees (FTE) 2021: 6.7 First fiscal year in the series	8.6 Employees (FTE) 2022: 8.6 ▲ 1.9 vs 2021 (6.7) Unchanged	9.4 Employees (FTE) 2023: 9.4 ▲ 0.8 vs 2022 (8.6) Unchanged	8.9 Employees (FTE) 2024: 8.9 ▼ 0.5 vs 2023 (9.4) Unchanged	▼ 0.5

Key figures of ZELLIK PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to ZELLIK PHARMA?

What happened at ZELLIK PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 23, 2025 New annual accounts for financial year 2024: loss of € 93,373 (▼ € 161,938 vs 2023). Source: NBB ↗
2018 Pharma Force NV became a director. NBB
Jun 16, 2006 Start of the company according to the CBE. KBO
Jun 10, 2006 New establishment in Dilbeek. KBO

In short

From € 115,718 profit in 2021 to € 93,373 loss in 2024.

Paid € 110,584 in corporate taxes since 2021.

Best year ever: 2021, with € 115,718 profit.

On average € 44,200 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

peeters mathieu management 100%

The stake of peeters mathieu management comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ZELLIK PHARMA

Behind ZELLIK PHARMA is Pharma Force NV. The shares are held by peeters mathieu management (100%).

Directors

According to the 2024 annual accounts

Pharma Force NV

Director · represented by Mathieu Peeters

Also active at: Pharma2Care, PHARMA BASE

since 2018

Shareholders

peeters mathieu management

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Brusselsesteenweg 812

1731 Asse

2.156.122.532

Elzenstraat 4

1702 Dilbeek

Active since 10 June 2006

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0881.910.538

VAT number

BE 0881.910.538

Registered office

Brusselsesteenweg 812, 1731 Asse

Names & denominations

ZELLIK PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

16 June 2006

Peppol

Active · Active since 13 Jun 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

ZELLIK PHARMA

Financials

What happened to ZELLIK PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions